Cellipont Bioservices supports six client projects for IND submission in 2026

THE WOODLANDS, Texas, Sept. 3, 2026 /CourierPR/ -- Cellipont Bioservices, a contract development and manufacturing organization focused on cell therapies, has announced that its Texas facility has supported six client projects that are expected to reach Investigational New Drug (IND) submission in 2026. This milestone underscores the company's capabilities in advancing complex cell therapy programs through integrated services including process development, analytical development, Good Manufacturing Practice (GMP) manufacturing, and quality testing.

Preparing a cell therapy program for an IND submission is a multifaceted process that requires coordination among scientific, technical, operational, and quality teams. For each client, Cellipont develops a tailored strategy that may include process optimization, analytical method development, technology transfer, raw material planning, GMP manufacturing, quality control testing, stability support, and the preparation of manufacturing and analytical information for the submission.

"Supporting a growing portfolio of cell therapy programs, including six client projects that are expected to reach IND submission in 2026, is a meaningful demonstration of the capabilities we have built," stated Darren Head, CEO of Cellipont Bioservices. "Each program has unique scientific and manufacturing requirements, and advancing these IND-enabling efforts in parallel reflects the experience, collaboration, and dedication of our entire team."

Cellipont's purpose-built facility in The Woodlands, Texas, supports both autologous and allogeneic cell therapy programs from early development through clinical manufacturing. By engaging early and acting as an extension of its clients' teams, Cellipont helps identify and mitigate risks, maintain momentum, and prepare programs for their next stage of development.

"We are incredibly proud of the Cellipont team and the commitment they bring to every client program," Head added. "Supporting six anticipated IND submissions so far in 2026 is a significant accomplishment and a strong reflection of our patient-focused culture."

The Cellipont facility is designed to handle both autologous and allogeneic cell therapy programs, from early development through clinical manufacturing. By working closely with its clients, Cellipont ensures that programs are well-prepared for the next phase of development, addressing the unique scientific and manufacturing challenges each program faces.

According to Head, the company’s commitment to excellence in all aspects of its operations has enabled it to support the six client projects expected to reach IND submission in 2026. This milestone highlights Cellipont's ability to deliver comprehensive solutions for cell therapy development and manufacturing, ensuring that its clients can bring life-changing therapies to patients worldwide.